Clinical Research Directory

Inclusion Criteria: * • Able and willing to provide written informed consent and comply with all study procedures. * Healthy male or female adults aged 18 to 55 years at the time of informed consent. * Body mass index (BMI) 19-26 kg/m²; body weight ≥50 kg (males) and ≥45 kg (females). * Medically healthy with no clinically significant abnormalities in medical history, physical examination, vital signs, laboratory tests, or 12-lead ECG, as determined by the investigator. * Women of childbearing potential and male subjects with partners of childbearing potential must agree to use effective contraception from screening through 3 months after the last dose of investigational product. Exclusion Criteria: * History or presence of any clinically significant disease (including cardiovascular, neurological, psychiatric, gastrointestinal, hepatic, renal, hematologic, endocrine, or immune disorders) that may interfere with study participation or data interpretation. * Personal or family history of clinically significant cardiac disease, including QT prolongation, torsades de pointes, myocardial infarction, heart failure, or sudden cardiac death. * Use of medications known to prolong QT/QTc interval or treatment for clinically significant cardiac conditions. * Screening 12-lead ECG abnormalities, including QTcF \>450 ms (males) or \>470 ms (females), PR interval \>210 ms, QRS duration \>110 ms, clinically significant arrhythmias, or uncontrolled hypertension. * Participation in another interventional clinical trial or receipt of any investigational drug within 3 months prior to first dosing. * Blood donation or significant blood loss (≥400 mL) within 3 months prior to first dosing. * Pregnant or breastfeeding women, or positive pregnancy test at screening or prior to dosing. * Positive tests for HBsAg, HCV antibody, HIV antibody, or syphilis. * History of drug or alcohol abuse, positive drug screen, or inability to abstain from alcohol, nicotine, or prohibited substances during the study. * Use of prescription or non-prescription medications, herbal products, supplements, or vaccines within 28 days prior to dosing, unless approved by the investigator. * Any condition that, in the opinion of the investigator, would make the subject unsuitable for participation in the study.